Added to YB: 2026-04-14
Pitch date: 2026-04-10
CNTX [bullish]
Context Therapeutics Inc.
-0.81%
current return
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors.
Market Cap
$228.8M
Pitch Price
$2.48
Price Target
7.00 (+181%)
Dividend
N/A
EV/EBITDA
-4.12
P/E
-6.56
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
DD: Context Therapeutics ($CNTX)
CNTX: T-cell engager targeting Claudin 6 for ovarian/testicular cancers. CTIM-76 cleared 560µg dose w/o CRS (cytokine release syndrome) risk vs peers. June 2026 Phase 1a data = key catalyst. Fast Track granted Apr 2026. $66M cash ($1.15/sh floor), runway to mid-2027. Bull: >30% ORR → $850M valuation. Bear: toxicity/weak efficacy at higher doses. M&A target for Merck/Amgen/Gilead. 30% POS, $7 PT (+170% upside) on risk-adjusted DCF.
Read full article (7 min)